Lipum AB (publ) has published the interim report for period January to March for 2023. Below is a summary, a complete report (only in Swedish) is available on the company's website. CEO Einar Pontén comments: “I am excited about our ongoing Phase 1 clinical trial of the drug candidate SOL-116 as everything is going according [...]
Lipum AB (publ) has published the interim and the year-end report for 2022. Below is a summary, a complete report (only in Swedish) is available on the company's website. CEO Einar Pontén comments: “In the fourth quarter, we started a first in man phase 1 clinical trial of our drug candidate SOL-116, achieving the major [...]
Lipum AB (publ) announces that the clinical phase 1 study with the drug candidate SOL-116 is proceeding as planned. After a fourth dose escalation, a safety evaluation has now been conducted and as expected, data show that SOL-116 remains safe and well tolerated. The study is therefore continuing as planned with a higher dose level [...]
Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming events. BIO-Europe Spring | March 20–22, 2023 | Basel, SwitzerlandLSX World Congress | May 3-4, 2023 | London, UKRedeye Investor Forum | May 11, 2023 | Malmö, SwedenBioStock Life Science Summit Spring | May 30-31, 2023 | DigitalBIO International [...]
Lipum AB (publ) ("Lipum") announces its Nomination Committee for the Annual General Meeting 2023. In accordance with the decision at the Annual General Meeting, the three largest shareholders in terms of voting rights on 1 September 2022 have appointed a Nomination Committee for the Annual General Meeting 2023. The three largest shareholders in terms of [...]
Lipum AB has published the interim report for period July-September 2022. Below is a short summary, a complete report (only in Swedish) is available on the company's website. CEO Einar Pontén comments: “In early November, we were able to report that our Phase 1 clinical trial had started. Preparations for this were a major activity [...]
Lipum AB (publ) announces that the Phase 1 clinical study with the drug candidate SOL-116 has started and is progressing according to plan. To date, a first dose group of eight healthy volunteers have received a dose, with two of the volunteers receiving placebo. The drug candidate SOL-116 is a fully humanised antibody that, through [...]
Press release: Umeå, October 19, 2022. Lipum AB (publ) (“Lipum” or the “Company”) announces that the directed share issue of approximately SEK 39 million before deduction of transaction costs (the “Directed Share Issue”) has been fully subscribed.The Board of Directors of Lipum resolved on September 22, 2022, subject to the approval by the General Meeting, on [...]
Press release: Umeå, October 12, 2022. The Extraordinary General Meeting (the “EGM”) in Lipum AB (publ), corporate identity number 556813-5999 (”Lipum” or the “Company”), today resolved to approve the Board of Directors’ resolution on a directed share issue of 2,601,732 new shares.The EGM resolved to approve the Board of Directors’ previous resolution on September 22, [...]
Press release: Umeå, 27 September, 2022. Lipum AB (publ) announces today that the CTA (clinical trial application) for the drug candidate SOL-116 has been approved by the regulatory authorities in The Netherlands.The study that includes healthy volunteers and patients with rheumatoid arthritis will be carried out at QPS BV facility in Groningen, Netherlands. The study [...]